Core Viewpoint - Zhongsheng Pharmaceutical experienced a 5.08% increase in stock price, reaching 22.33 CNY per share, with a trading volume of 1.919 billion CNY and a turnover rate of 11.62%, resulting in a total market capitalization of 18.979 billion CNY [1] Company Overview - Zhongsheng Pharmaceutical Co., Ltd. is located in Dongguan, Guangdong Province, established on December 31, 2001, and listed on December 11, 2009. The company focuses on the research, production, and sales of pharmaceuticals [1] - The revenue composition of the company includes: Traditional Chinese Medicine sales at 53.03%, chemical drug sales at 38.12%, Chinese medicinal materials and decoction pieces at 6.13%, raw materials and intermediates at 2.14%, and other (supplementary) at 0.58% [1] Fund Holdings - According to data from the top ten holdings of funds, one fund under Jianxin Fund has a significant position in Zhongsheng Pharmaceutical. Jianxin High-end Medical Stock A (004683) held 403,600 shares in the third quarter, accounting for 5.61% of the fund's net value, ranking as the fifth largest holding [2] - The estimated floating profit from this position is approximately 435,900 CNY [2] Fund Manager Information - The fund manager of Jianxin High-end Medical Stock A (004683) is Pan Longling, who has been in the position for 9 years and 230 days. The total asset size of the fund is 162 million CNY, with the best fund return during the tenure being 47.31% and the worst being -33.31% [3]

Core Insights - Nuo Cheng Jian Hua's stock increased by 5.09% to 23.96 CNY per share, with a total market capitalization of 42.281 billion CNY as of October 31 [1] Company Overview - Nuo Cheng Jian Hua Pharmaceutical Co., Ltd. is based in Beijing and was established on November 3, 2015, with its IPO on September 21, 2022 [1] - The company focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [1] - The revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and 0.15% each from testing and R&D services [1] Fund Holdings - Jianxin Fund has a significant position in Nuo Cheng Jian Hua, with its Jianxin High-end Medical Stock A fund holding 147,800 shares, representing 3.39% of the fund's net value [2] - The fund has generated an estimated floating profit of approximately 171,500 CNY today [2] Fund Manager Information - The fund manager of Jianxin High-end Medical Stock A is Pan Longling, who has been in the position for 9 years and 218 days [3] - The fund's total asset size is 162 million CNY, with a best return of 48.64% and a worst return of -31% during the manager's tenure [3]